Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
Status:
RECRUITING
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer.
Trial details include:
* The trial duration will be up to approximately 11 months.
* The treatment duration will be up to approximately 4 months (the duration of treatment may vary for each participant) and the follow-up duration will be approximately 6 months.
Participation in the trial will require visits to the site. All participants will receive active drug; no one will be given placebo.